Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP) – Leerink Swann issued their Q3 2016 EPS estimates for shares of Aquinox Pharmaceuticals in a report issued on Tuesday. Leerink Swann analyst P. Matteis expects that the firm will post earnings of ($0.58) per share for the quarter. Leerink Swann currently has a “Outperform” rating and a $24.00 target price on the stock. Leerink Swann also issued estimates for Aquinox Pharmaceuticals’ Q4 2016 earnings at ($0.56) EPS, FY2016 earnings at ($2.51) EPS and FY2017 earnings at ($2.63) EPS.
A number of other brokerages have also issued reports on AQXP. Zacks Investment Research raised Aquinox Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday. Jefferies Group boosted their target price on Aquinox Pharmaceuticals from $7.00 to $9.00 and gave the stock a “hold” rating in a research report on Friday, August 5th. Finally, Canaccord Genuity reaffirmed a “buy” rating and set a $22.00 target price on shares of Aquinox Pharmaceuticals in a research report on Wednesday, August 17th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Aquinox Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $20.00.
Shares of Aquinox Pharmaceuticals (NASDAQ:AQXP) opened at 13.56 on Thursday. The company’s 50 day moving average price is $12.45 and its 200 day moving average price is $9.17. The stock’s market capitalization is $233.39 million. Aquinox Pharmaceuticals has a one year low of $6.01 and a one year high of $16.75.
Aquinox Pharmaceuticals (NASDAQ:AQXP) last announced its earnings results on Thursday, August 4th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.41) by $0.22.
In other Aquinox Pharmaceuticals news, major shareholder Bros. Advisors Lp Baker purchased 2,783,605 shares of the stock in a transaction dated Tuesday, September 20th. The shares were acquired at an average price of $12.25 per share, for a total transaction of $34,099,161.25. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 3.00% of the company’s stock.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Goldman Sachs Group Inc. increased its position in shares of Aquinox Pharmaceuticals by 5,277.2% in the first quarter. Goldman Sachs Group Inc. now owns 970,317 shares of the company’s stock worth $8,558,000 after buying an additional 952,272 shares in the last quarter. Opaleye Management Inc. acquired a new position in shares of Aquinox Pharmaceuticals during the second quarter worth $1,953,000. Franklin Resources Inc. increased its position in shares of Aquinox Pharmaceuticals by 7.6% in the first quarter. Franklin Resources Inc. now owns 1,245,945 shares of the company’s stock worth $10,989,000 after buying an additional 87,600 shares in the last quarter. Royce & Associates LP increased its position in shares of Aquinox Pharmaceuticals by 89.9% in the second quarter. Royce & Associates LP now owns 182,622 shares of the company’s stock worth $1,209,000 after buying an additional 86,455 shares in the last quarter. Finally, Boxer Capital LLC increased its position in shares of Aquinox Pharmaceuticals by 7.0% in the second quarter. Boxer Capital LLC now owns 877,753 shares of the company’s stock worth $5,811,000 after buying an additional 57,738 shares in the last quarter. Institutional investors and hedge funds own 68.20% of the company’s stock.
About Aquinox Pharmaceuticals